The firm has begun dosing extensive-stage small cell and Merkel cell cancer patients with 225Ac-SSO110 in a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback